TY - JOUR
T1 - Matrix metalloproteinase levels in early HIV infection and relation to in vivo brain status
AU - Li, Suyang
AU - Wu, Ying
AU - Keating, Sheila M.
AU - Du, Hongyan
AU - Sammet, Christina L.
AU - Zadikoff, Cindy
AU - Mahadevia, Riti
AU - Epstein, Leon G.
AU - Ragin, Ann B.
N1 - Funding Information:
The authors thank Paul Foryt and Yi Gao. This work was supported by a National Institutes of Health grant [ABR MH080636].
PY - 2013/10
Y1 - 2013/10
N2 - Matrix metalloproteinases (MMPs) have been implicated in human immunodeficiency virus (HIV)-associated neurological injury; however, this relationship has not been studied early in infection. Plasma levels of MMP-1, MMP-2, MMP-7, MMP-9, and MMP-10 measured using Luminex technology (Austin, TX, USA) were compared in 52 HIV and 21 seronegative participants of the Chicago Early HIV Infection study. MMP levels were also examined in HIV subgroups defined by antibody reactivity, viremia, and antiretroviral status, as well as in available cerebrospinal fluid (CSF) samples (n = 9). MMPs were evaluated for patterns of relationship to cognitive function and to quantitative magnetic resonance measurements of the brain derived in vivo. Plasma MMP-2 levels were significantly reduced in early HIV infection and correlated with altered white matter integrity and atrophic brain changes. MMP-9 levels were higher in the treated subgroup than in the naïve HIV subgroup. Only MMP-2 and MMP-9 were detected in the CSF; CSF MMP-2 correlated with white matter integrity and with volumetric changes in basal ganglia. Relationships with cognitive function were also identified. MMP-2 levels in plasma and in CSF correspond to early changes in brain structure and function. These findings establish a link between MMPs and neurological status previously unidentified in early HIV infection.
AB - Matrix metalloproteinases (MMPs) have been implicated in human immunodeficiency virus (HIV)-associated neurological injury; however, this relationship has not been studied early in infection. Plasma levels of MMP-1, MMP-2, MMP-7, MMP-9, and MMP-10 measured using Luminex technology (Austin, TX, USA) were compared in 52 HIV and 21 seronegative participants of the Chicago Early HIV Infection study. MMP levels were also examined in HIV subgroups defined by antibody reactivity, viremia, and antiretroviral status, as well as in available cerebrospinal fluid (CSF) samples (n = 9). MMPs were evaluated for patterns of relationship to cognitive function and to quantitative magnetic resonance measurements of the brain derived in vivo. Plasma MMP-2 levels were significantly reduced in early HIV infection and correlated with altered white matter integrity and atrophic brain changes. MMP-9 levels were higher in the treated subgroup than in the naïve HIV subgroup. Only MMP-2 and MMP-9 were detected in the CSF; CSF MMP-2 correlated with white matter integrity and with volumetric changes in basal ganglia. Relationships with cognitive function were also identified. MMP-2 levels in plasma and in CSF correspond to early changes in brain structure and function. These findings establish a link between MMPs and neurological status previously unidentified in early HIV infection.
KW - Acute HIV
KW - Diffusion tensor imaging
KW - HIV-associated neurocognitive disorder
KW - Matrix metalloproteinases
KW - Neuro-AIDS
UR - http://www.scopus.com/inward/record.url?scp=84885619435&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84885619435&partnerID=8YFLogxK
U2 - 10.1007/s13365-013-0197-3
DO - 10.1007/s13365-013-0197-3
M3 - Article
C2 - 23979706
AN - SCOPUS:84885619435
VL - 19
SP - 452
EP - 460
JO - Journal of NeuroVirology
JF - Journal of NeuroVirology
SN - 1355-0284
IS - 5
ER -
